- Home
- XNCR vs PHAT Comparison
XNCR vs PHAT Comparison
Compare XNCR & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNCR | PHAT |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 881.9M | 894.0M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | XNCR | PHAT |
|---|---|---|
| Price | $11.21 | $11.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $22.33 | $19.83 |
| AVG Volume (30 Days) | 712.4K | ★ 1.3M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | 42.72 |
| EPS | N/A | ★ N/A |
| Revenue | $125,576,000.00 | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | $4.80 | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.65 | ★ 216.93 |
| 52 Week Low | $6.92 | $3.92 |
| 52 Week High | $18.69 | $18.31 |
Technical Indicators
Market Signals| Indicator | XNCR | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 43.75 |
| Support Level | $11.02 | $11.04 |
| Resistance Level | $13.28 | $12.83 |
| Average True Range (ATR) | 0.72 | 0.73 |
| MACD | -0.16 | -0.13 |
| Stochastic Oscillator | 24.53 | 8.04 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.